Alpha Teknova Intrinsic Value Calculator – ALPHA TEKNOVA Reports Q2 FY2023 Earnings of USD 11.5 Million, Down 1.4% Year-on-Year.

August 23, 2023

🌥️Earnings Overview

On August 10, 2023, ALPHA TEKNOVA ($NASDAQ:TKNO) reported its second quarter FY2023 earnings results, showing total revenue of USD 11.5 million, a 1.4% decrease year-over-year. Additionally, net income for the quarter was USD -7.2 million, a slight improvement from -6.2 million in Q2 FY2022.

Analysis – Alpha Teknova Intrinsic Value Calculator

GoodWhale has conducted an analysis of ALPHA TEKNOVA‘s wellbeing and determined that the fair value of ALPHA TEKNOVA share is around $10.6. This value was determined by GoodWhale’s proprietary Valuation Line, which factors in various variables to calculate a company’s fair market value. At the moment, ALPHA TEKNOVA stock is trading at $2.8, which is significantly undervalued by 73.6%. This presents an opportunity for savvy investors to purchase the stock at a discounted rate. Furthermore, the current situation also indicates that ALPHAT TEKNOVA’s stock may be set to increase in value as the company continues to make positive strides. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Alpha Teknova. More…

    Total Revenues Net Income Net Margin
    39.23 -51.74 -74.6%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Alpha Teknova. More…

    Operations Investing Financing
    -27.9 -17.96 4.97
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Alpha Teknova. More…

    Total Assets Total Liabilities Book Value Per Share
    132.55 46.34 3.05
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Alpha Teknova are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    27.3% -76.8%
    FCF Margin ROE ROA
    -116.9% -21.1% -14.2%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The company’s main competitors are Sunshine Biopharma Inc, SCYNEXIS Inc, and Antisense Therapeutics Ltd. All three companies are engaged in the development of new and innovative treatments for various diseases and disorders.

    – Sunshine Biopharma Inc ($NASDAQ:SBFM)

    Sunshine Biopharma Inc. is a pharmaceutical company that focuses on the development and commercialization of cancer and anti-infective drugs. The company’s market cap is $17.09 million and its ROE is -3.82%. Sunshine Biopharma’s products in development include Adva-27a, a treatment for ovarian and other types of cancer; and Amiket, a treatment for ketamine addiction.


    SCYNEXIS Inc is a biopharmaceutical company that focuses on the development and commercialization of novel anti-infectives to address unmet needs in the treatment of serious and life-threatening infections. The company’s lead product, SCY-078, is a novel oral and intravenous (IV) antifungal agent in Phase 3 clinical development for the treatment of vulvovaginal candidiasis (VVC), also known as yeast infection, and invasive fungal infections, such as candidemia and other serious fungal infections.

    – Antisense Therapeutics Ltd ($ASX:ANP)

    Antisense Therapeutics Ltd is a pharmaceutical company that develops drugs to treat cancer and other diseases. The company has a market capitalization of $66.88 million and a return on equity of -21.12%. Antisense Therapeutics Ltd develops drugs that target the genetic causes of disease. The company’s drugs are designed to silence disease-causing genes. Antisense Therapeutics Ltd’s products are in clinical trials for the treatment of cancer, Huntington’s disease, and amyotrophic lateral sclerosis.


    Alpha Teknova’s second quarter FY2023 earnings report showed total revenue of USD 11.5 million, a decrease of 1.4% compared to the same quarter the previous year, and a net income of -7.2 million which was an improvement from -6.2 million the previous year. Despite the slight revenue decline, the stock price was positively affected by the improved net income, moving up the same day as the report was released. Investors should take into account this information when considering Alpha Teknova as a potential investment, paying particular attention to the company’s ability to maintain a positive net income despite declining revenues and how this might influence the future of the stock.

    Recent Posts

    Leave a Comment